Opus Genetics reports Q3 2026 results, multiple IRD gene therapy milestonesNov 10Quarterly updateOcuphire Pharma, Inc.
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
FDA approves efficacy supplement for Famygen's Ryzumvi eye dropsOct 16Regulatory decisionphentolamine
Viatris: Ocuphire trial results posted, Amnesteem label update, gabapentin abuse study completedAug 21Weekly roundup, 3 itemsalprazolamgabapentin
Ocuphire's Phase 3 VEGA-3 presbyopia trial posts results on ClinicalTrials.govAug 17Trial updateOcuphire Pharma, Inc.